我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
9
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1982
进行中（未招募）
1
11.1%
已完成
5
55.6%
招募中
2
22.2%
撤回
暂无批准数据
- Bexorg has been awarded a research grant from The Michael J. Fox Foundation to identify translational biomarkers for TRPML1-targeted Parkinson's disease therapies using its postmortem whole-human brain platform. - TRPML1 has emerged as a compelling therapeutic target for Parkinson's disease, but the lack of translational biomarkers to confirm target engagement in clinical trials has been a significant obstacle. - The company will leverage its proprietary BrainEx platform to identify biomarkers in brains donated by people who lived with Parkinson's disease, potentially accelerating multiple TRPML1-targeted therapeutic programs. - Bexorg's approach addresses the critical translational gap in CNS drug development, where clinical trial failure rates exceed 95% due to inadequate preclinical models.
